

Title (en)  
CYCLOPENTANE AND CYCLOPENTENE DERIVATIVES WITH ANTIALLERGIC ANTIINFLAMMATORY AND TUMOR NECROSIS FACTOR INHIBITING ACTIVITY.

Title (de)  
CYCLOPENTAN- UND CYCLOPENTEN-DERIVATE MIT ANTIALLERGISCHEN, ENTZÜNDUNGSGEMINDERNDEN UND TUMOR NECROSE FAKTOR INHIBIERENDEN EIGENSCHAFTEN.

Title (fr)  
CYCLOPENTANE ET DERIVES DE CYCLOPENTANE PRESENTANT UNE ACTIVITE ANTIALLERGIQUE, ANTI-INFLAMMATOIRE ET INHIBANT LE FACTEUR NECROTIQUE TUMORAL.

Publication  
**EP 0642489 A1 19950315 (EN)**

Application  
**EP 92921752 A 19921001**

Priority  

- US 9208609 W 19921001
- US 77106291 A 19911002

Abstract (en)  
[origin: WO9307111A1] Compounds illustrated by general formula (I) useful as PDE IV inhibitors and for inhibiting the production of Tumor Necrosis Factor (TNF) are disclosed herein. In formula (I) R1 is C1-12 alkyl unsubstituted or substituted by 1 or more halogens; C3-6 cyclic alkyl unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group; C4-6 cycloalkyl containing one or two unsaturated bonds; C7-11 polycycloalkyl, -(CR14R14)nC(O)-O-(CR14R14)m-R10, -(CR14R14)nC(O)-O-(CR14R14)r-R11, -(CR14R14)xOH, -(CR14R14)sO(CR14R14)m-R10, -(CR14R14)sO(CR14R14)r-R11, -(CR14R14)n-(C(O)NR14)-(CR14R14)m-R10, -(CR14R14)n-(C(O)NR14)-(CR14R14)r-R11, -(CR14R14)y-R11 or -(CR14R14)z-R10; X2 is O or NR14; X3 is hydrogen or X; X is YR2, halogen, nitro, NR14R14 or formamide; Y is O or S(O)m; R2 is -CH3 or -CH2CH3, each may be unsubstituted or substituted by 1 to 5 fluorines; A is (a), (b), (c), (d) or (e); B is >C=Z or C=S.

IPC 1-7  
**C07C 49/753; C07C 69/757; C07C 62/34; C07C 235/40; A61K 31/12; A61K 31/215; A61K 31/195; A61K 31/16**

IPC 8 full level  
**A61K 31/122** (2006.01); **A61K 31/165** (2006.01); **A61K 31/192** (2006.01); **A61K 31/194** (2006.01); **A61K 31/216** (2006.01); **A61K 31/277** (2006.01); **A61K 31/41** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/4409** (2006.01); **A61P 11/06** (2006.01); **A61P 29/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/08** (2006.01); **C07C 45/62** (2006.01); **C07C 45/68** (2006.01); **C07C 45/70** (2006.01); **C07C 49/753** (2006.01); **C07C 59/72** (2006.01); **C07C 62/12** (2006.01); **C07C 62/34** (2006.01); **C07C 69/734** (2006.01); **C07C 69/757** (2006.01); **C07C 217/52** (2006.01); **C07C 229/48** (2006.01); **C07C 233/23** (2006.01); **C07C 233/25** (2006.01); **C07C 233/43** (2006.01); **C07C 235/40** (2006.01); **C07C 237/42** (2006.01); **C07C 237/44** (2006.01); **C07C 251/44** (2006.01); **C07C 255/46** (2006.01); **C07C 317/22** (2006.01); **C07C 317/32** (2006.01); **C07C 323/24** (2006.01); **C07D 213/40** (2006.01); **C07D 235/02** (2006.01); **C07D 257/04** (2006.01)

CPC (source: EP)  
**A61P 11/06** (2017.12); **A61P 29/00** (2017.12); **A61P 37/00** (2017.12); **A61P 37/08** (2017.12); **C07C 45/62** (2013.01); **C07C 45/68** (2013.01); **C07C 45/70** (2013.01); **C07C 49/753** (2013.01); **C07C 62/12** (2013.01); **C07C 62/34** (2013.01); **C07C 69/734** (2013.01); **C07C 69/757** (2013.01); **C07C 217/52** (2013.01); **C07C 229/48** (2013.01); **C07C 233/23** (2013.01); **C07C 235/40** (2013.01); **C07C 251/44** (2013.01); **C07C 255/46** (2013.01); **C07D 213/40** (2013.01); **C07D 235/02** (2013.01); **C07C 2601/08** (2017.04); **C07C 2601/10** (2017.04)

C-Set (source: EP)  

- C07C 45/62 + C07C 49/753**
- C07C 45/68 + C07C 49/753**
- C07C 45/70 + C07C 49/753**

Citation (search report)  
See references of WO 9307111A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

DOCDB simple family (publication)  
**WO 9307111 A1 19930415**; AU 2807192 A 19930503; CA 2120351 A1 19930415; EP 0642489 A1 19950315; JP 3333510 B2 20021015; JP H07500108 A 19950105; MX 9205680 A 19930501; NZ 244605 A 19950526; PT 100928 A 19931029; ZA 927591 B 19930413

DOCDB simple family (application)  
**US 9208609 W 19921001**; AU 2807192 A 19921001; CA 2120351 A 19921001; EP 92921752 A 19921001; JP 50720193 A 19921001; MX 9205680 A 19921002; NZ 24460592 A 19921002; PT 10092892 A 19921002; ZA 927591 A 19921002